Avoro Capital Advisors LLC Has $155.92 Million Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Avoro Capital Advisors LLC trimmed its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 18.1% in the second quarter, Holdings Channel.com reports. The institutional investor owned 4,309,590 shares of the company’s stock after selling 955,410 shares during the period. Vera Therapeutics makes up about 2.1% of Avoro Capital Advisors LLC’s holdings, making the stock its 16th largest holding. Avoro Capital Advisors LLC owned about 0.08% of Vera Therapeutics worth $155,921,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the company. Kynam Capital Management LP lifted its position in Vera Therapeutics by 23.5% during the 4th quarter. Kynam Capital Management LP now owns 3,650,339 shares of the company’s stock worth $56,142,000 after acquiring an additional 694,286 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of Vera Therapeutics during the 1st quarter worth about $103,189,000. Vanguard Group Inc. boosted its stake in Vera Therapeutics by 31.5% during the 1st quarter. Vanguard Group Inc. now owns 2,148,714 shares of the company’s stock valued at $92,653,000 after purchasing an additional 515,106 shares during the period. Schroder Investment Management Group acquired a new stake in Vera Therapeutics in the 4th quarter valued at approximately $17,087,000. Finally, Artal Group S.A. bought a new position in Vera Therapeutics in the 1st quarter worth approximately $21,820,000. 99.21% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Vera Therapeutics news, Director Beth C. Seidenberg sold 1,177 shares of the company’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $42.01, for a total value of $49,445.77. Following the sale, the director now directly owns 160,376 shares in the company, valued at $6,737,395.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Marshall Fordyce sold 14,471 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $39.76, for a total value of $575,366.96. Following the completion of the transaction, the chief executive officer now owns 322,667 shares in the company, valued at $12,829,239.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Beth C. Seidenberg sold 1,177 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $42.01, for a total value of $49,445.77. Following the completion of the transaction, the director now directly owns 160,376 shares in the company, valued at $6,737,395.76. The disclosure for this sale can be found here. Insiders sold 31,273 shares of company stock worth $1,210,750 in the last 90 days. 21.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

VERA has been the subject of several research reports. Evercore ISI raised Vera Therapeutics to a “strong-buy” rating in a research report on Monday, September 16th. Cantor Fitzgerald reiterated an “overweight” rating and set a $107.00 target price on shares of Vera Therapeutics in a research note on Monday, September 16th. Finally, JPMorgan Chase & Co. raised their price target on shares of Vera Therapeutics from $62.00 to $72.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $51.75.

Vera Therapeutics Trading Up 1.9 %

Shares of VERA stock opened at $42.78 on Monday. The firm has a fifty day moving average of $37.47 and a 200-day moving average of $39.00. The stock has a market cap of $2.34 billion, a price-to-earnings ratio of -20.87 and a beta of 0.99. Vera Therapeutics, Inc. has a 52-week low of $9.24 and a 52-week high of $50.78. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.43 and a current ratio of 21.43.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.06). On average, equities research analysts forecast that Vera Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.